Susquehanna International Group, LLP Intellia Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	BUY	$20.02 - $27.22 $812,812 - $1.11 Million	40,600 Added 15.84%	296,900 $6.64 Million
Q1 2024 May 07, 2024	BUY	$23.82 - $32.8 $445,434 - $613,360	18,700 Added 7.87%	256,300 $7.05 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $3.04 Million - $4.25 Million	131,400 Added 123.73%	237,600 $7.24 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $218,178 - $315,882	-6,900 Reduced 6.1%	106,200 $3.36 Million
Q2 2023 Aug 11, 2023	BUY	$34.58 - $46.03 $138,320 - $184,120	4,000 Added 3.67%	113,100 $4.61 Million
Q1 2023 May 16, 2023	BUY	$33.3 - $44.82 $546,120 - $735,048	16,400 Added 17.69%	109,100 $4.07 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $3.85 Million - $7.27 Million	-116,000 Reduced 55.58%	92,700 $3.23 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $6.26 Million - $8.32 Million	116,100 Added 125.38%	208,700 $11.7 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $619,689 - $1.23 Million	-16,100 Reduced 14.81%	92,600 $4.79 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $174,810 - $356,970	3,000 Added 2.84%	108,700 $7.9 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $1.69 Million - $2.32 Million	-16,800 Reduced 13.71%	105,700 $12.5 Million
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $18.5 Million - $24.7 Million	-139,900 Reduced 53.32%	122,500 $16.4 Million
Q2 2021 Aug 11, 2021	BUY	$60.88 - $161.91 $1.85 Million - $4.92 Million	30,400 Added 13.1%	262,400 $42.5 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $7.81 Million - $14 Million	167,600 Added 260.25%	232,000 $18.6 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $64,021 - $216,002	3,400 Added 5.57%	64,400 $3.5 Million
Q3 2020 Nov 16, 2020	SELL	$17.47 - $24.93 $487,412 - $695,547	-27,900 Reduced 31.38%	61,000 $1.21 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $482,362 - $990,271	43,300 Added 94.96%	88,900 $1.87 Million
Q1 2020 May 15, 2020	BUY	$9.44 - $15.58 $326,624 - $539,068	34,600 Added 314.55%	45,600 $558,000
Q4 2019 Feb 14, 2020	SELL	$10.43 - $17.67 $168,966 - $286,254	-16,200 Reduced 59.56%	11,000 $161,000
Q3 2019 Nov 14, 2019	SELL	$13.07 - $18.51 $30,061 - $42,573	-2,300 Reduced 7.8%	27,200 $363,000
Q2 2019 Aug 14, 2019	SELL	$13.88 - $18.41 $512,172 - $679,329	-36,900 Reduced 55.57%	29,500 $483,000
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $209,756 - $288,968	-16,400 Reduced 19.81%	66,400 $1.13 Million
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $264,248 - $629,416	23,200 Added 38.93%	82,800 $1.13 Million
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $1.88 Million - $2.37 Million	-72,800 Reduced 54.98%	59,600 $1.71 Million
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $140,140 - $215,530	7,000 Added 5.58%	132,400 $3.62 Million
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $1.62 Million - $2.91 Million	83,200 Added 197.16%	125,400 $2.65 Million
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $43,475 - $77,800	2,500 Added 6.3%	42,200 $811,000
Q3 2017 Nov 14, 2017	BUY	$15.16 - $25.75 $601,852 - $1.02 Million	39,700	39,700 $987,000

Others Institutions Holding NTLA

# of Institutions

326

Shares Held

88.8M

Call Options Held

673K

Put Options Held

865K

Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

11.6M
Shares

$223 Million
2.36% of portfolio
Black Rock Inc. New York, NY

9.6M
Shares

$184 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

9.1M
Shares

$175 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.8M
Shares

$92.2 Million
3.53% of portfolio
State Street Corp Boston, MA

4.36M
Shares

$83.8 Million
0.0% of portfolio

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.46B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account